GLP-1 & Incretin Science

Danuglipron: The Oral GLP-1 Pfizer Stopped

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Danuglipron, or PF-06882961, was Pfizer's oral small-molecule GLP-1 receptor agonist for chronic weight management. Development was discontinued in April 2025 after a single asymptomatic participant experienced potential drug-induced liver injury, which resolved after the drug was stopped.

Key facts

Development code
PF-06882961
Developer
Pfizer
Class
Oral small-molecule GLP-1 receptor agonist
Phase 2b published
Diabetes Obes Metab 2025 (PMID 40539310)
Discontinued
April 2025
Trigger
One asymptomatic DILI case, resolved on stopping
Safety database
Over 1,400 participants
Enzyme elevations overall
In line with approved agents in the class

What it was

A non-peptide GLP-1 receptor agonist small enough to survive the digestive tract and be absorbed as an ordinary tablet, the same basic proposition as orforglipron and aleniglipron. Its Phase 2b results in adults with obesity were published in Diabetes, Obesity and Metabolism in September 2025, after the programme had already been stopped.

Why the discontinuation is more interesting than it looks

The dose-optimisation studies had met their key pharmacokinetic objectives. Pfizer's own update stated that across a safety database of more than 1,400 participants, the frequency of liver enzyme elevations was in line with approved agents in the class. So the programme was not stopped because danuglipron looked worse than the drugs already on the market.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What actually ended it

One participant. A single asymptomatic case of potential drug-induced liver injury in a dose-optimisation study, which resolved after the drug was discontinued. Pfizer described the decision as following a review of the totality of information including regulator input, and concluded the risk-benefit profile did not support continuing.

Why one case can be decisive

Because of what obesity medicine is. A drug for a chronic condition, taken by very large numbers of people for years, with several effective alternatives already licensed, has almost no tolerance for a serious idiosyncratic risk. The same single case in a compound treating a condition with no alternatives would be weighed completely differently. Risk-benefit is a ratio, and the denominator here was crowded.

What it changed for everything that followed

It made hepatic safety the question every subsequent oral small molecule had to answer first. When the aleniglipron Phase 2b appeared in Nature Medicine in August 2026, the sentence that mattered to the field was not the 12.1% weight reduction. It was that no cases of drug-induced liver injury occurred. Most coverage led with the weight number.

What this does not concern

Research material of any kind. Danuglipron was an investigational medicine in registered clinical trials under clinical supervision, it was never licensed, and its development has ceased. Nothing supplied here is related to it or to any other GLP-1 receptor agonist.

Frequently asked questions

Why was danuglipron discontinued?

A single asymptomatic participant experienced potential drug-induced liver injury, which resolved after stopping. Pfizer concluded the risk-benefit profile did not support further development.

Were its liver signals worse than other GLP-1 drugs?

No. Pfizer stated that across over 1,400 participants, liver enzyme elevation frequency was in line with approved agents in the class.

Did the drug fail on efficacy?

No. The dose-optimisation studies met their key pharmacokinetic objectives before the programme was stopped.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.